Celgene – MMV Partnership

Partnership objective

This project aims to identify new therapies to treat blood and liver-stage malaria.

This partnership currently works to identify a single treatment that could be tested against various strains of malaria. This partnership currently works to identify a single treatment that could be tested against various strains of malaria. Copyright MMV

What are the health needs and challenges?

The worldwide disease burden for malaria is enormous, with more than half of the world at risk and with the development of resistance to existing therapies.

Description of partnership activities and how they address needs and challenges

In collaboration with Medicines for Malaria Venture (MMV), Celgene has developed numerous new classes of anti-malarial treatments from a screening against the major pathogen, Plasmodium falciparum. Currently, the work is focused on identifying a single treatment that could be tested against various strains of malaria.

Partnership information

Company(ies) Celgene

Partner(s) Medicines for Malaria Venture (MMV)

Type of Partner(s) PDPs

Therapeutic Focus Infectious Diseases

Disease(s) Malaria

Program Type(s) Research & Development - Development of Treatments

Targeted Population(s) Patients in needs of treatment

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, Middle East & North Africa, South Asia, Sub-Saharan Africa

Number of Countries 100

Country(ies) Afghanistan, Algeria, Angola, Argentina, Azerbaijan, Bangladesh, Belize, Benin, Bhutan, Bolivia, Botswana, Brazil, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, China, Colombia, Comoros, Congo, Costa Rica, Côte d'Ivoire, Democratic Republic of the Congo, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Eritrea, Ethiopia, Gabon, Ghana, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, India, Indonesia, Iran, Iraq, Jamaica, Kenya, Kyrgyzstan, Lao PDR, Liberia, Madagascar, Malawi, Malaysia, Mali, Mauritania, Mauritius, Mexico, Mozambique, Myanmar, Namibia, Nepal, Nicaragua, Niger, Nigeria, North Korea, Oman, Pakistan, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Rwanda, Sao Tome and Principe, Saudi Arabia, Senegal, Sierra Leone, Solomon Islands, Somalia, South Africa, South Korea, Sri Lanka, Sudan, Suriname, Swaziland, Syria, Tanzania, Thailand, The Gambia, Timor-Leste, Togo, Turkey, Uganda, Uzbekistan, Vanuatu, Venezuela, Vietnam, Yemen, Zambia, Zimbabwe

Start Date 2012

More information 2015 Celgene CSR Report

Anticipated completion date Ongoing